BioLife Solutions

BioLife Solutions is an American company that develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The Company supplies cryostor, hypothermosol, bloodstor, and other related products. BioLife Solutions was founded in 1987 and is headquartered in Bothell, Washington.
BioLife Solutions stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

BioLife Solutions balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

BioLife Solutions cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

BioLife Solutions multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

BioLife Solutions profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
BioLife Solutions assets
BioLife Solutions cash flows

BioLife Solutions dividend policy

The company doesn't provide dividend

BioLife Solutions shares

TickerNameTypeNominal valueISINPrice
BLFS:USBioLife SolutionsCommon share-US09062W2044$18.62
BioLife Solutions news
10.05.2022
BioLife Solutions' GAAP loss for 3 months of 2022 was $7.066 million, up 6.32 times from $1.118 million in the previous year. Revenue increased 2.15 times to $36.22 million from $16.847 million a year earlier.
01.03.2022
BioLife Solutions reported a GAAP loss of $8.383 million for 2021, compared to a profit of $2.667 million in the previous year. Revenue increased 2.5 times to $119.156 million from $48.087 million a year earlier.
12.11.2021
Net profit according to GAAP for 9 months of 2021 amounted to $6.837 million, increasing by 42.6% as compared to $4.795 million in the previous year. Revenue increased 2.5 times to $81.851 million from $33.361 million a year earlier.
01.09.2021
BioLife Solutions has completed the acquisition of Sexton Biotechnologies, which develops and sells biomanufacturing tools for cell and gene therapy. The amount of the deal is $24 million.
General information
Company nameBioLife Solutions
Tags#medtech
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Equipment
Business address3303 Monte Villa Parkway Suite 310 Bothell, WA 98021 United States
Mailing address3303 Monte Villa Parkway Suite 310 Bothell, WA 98021 United States
Websiteinvestors.biolifesolutions.com
Information disclosurewww.sec.gov